- Home
- DHY vs TIL Comparison
DHY vs TIL Comparison
Compare DHY & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- TIL
- Stock Information
- Founded
- DHY 1998
- TIL 2018
- Country
- DHY United States
- TIL United States
- Employees
- DHY N/A
- TIL N/A
- Industry
- DHY Finance/Investors Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- TIL Health Care
- Exchange
- DHY Nasdaq
- TIL Nasdaq
- Market Cap
- DHY 212.4M
- TIL 171.7M
- IPO Year
- DHY N/A
- TIL 2021
- Fundamental
- Price
- DHY $2.05
- TIL $29.65
- Analyst Decision
- DHY
- TIL Buy
- Analyst Count
- DHY 0
- TIL 5
- Target Price
- DHY N/A
- TIL $119.00
- AVG Volume (30 Days)
- DHY 569.1K
- TIL 359.9K
- Earning Date
- DHY 01-01-0001
- TIL 05-13-2025
- Dividend Yield
- DHY 9.10%
- TIL N/A
- EPS Growth
- DHY N/A
- TIL N/A
- EPS
- DHY N/A
- TIL N/A
- Revenue
- DHY N/A
- TIL N/A
- Revenue This Year
- DHY N/A
- TIL N/A
- Revenue Next Year
- DHY N/A
- TIL N/A
- P/E Ratio
- DHY N/A
- TIL N/A
- Revenue Growth
- DHY N/A
- TIL N/A
- 52 Week Low
- DHY $1.77
- TIL $9.62
- 52 Week High
- DHY $2.08
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- DHY 51.40
- TIL 68.29
- Support Level
- DHY $1.92
- TIL $23.47
- Resistance Level
- DHY $2.00
- TIL $35.28
- Average True Range (ATR)
- DHY 0.02
- TIL 4.40
- MACD
- DHY 0.00
- TIL 1.58
- Stochastic Oscillator
- DHY 50.00
- TIL 66.50
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.